Abstract
Thrombopoietin receptor agonist (TPORA) is a kind of medicine which can specifically combine with thrombopoietin (TPO) receptor (c-mpl) and take effect. Because of the advantages such as abundant source, easy access, no risk of donor, low requirement of human leukocyte antigen (HLA) matching, low incidence and mild degree of graft versus host disease (GVHD), etc., cord blood transplantation (CBT) has been widely applied in treatment of malignancy hematologic disease. In this paper, the biological characteristics of TPORA and its application in CBT are reviewed. Key words: Receptors, thrombopoietin; Cord blood stem cell transplantation; Graft vs host disease
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
